{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:43:39Z","timestamp":1794667419072,"version":"4.9.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI129910"],"award-info":[{"award-number":["U19AI129910"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI172887"],"award-info":[{"award-number":["R01AI172887"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"U.S. Department of Health & Human Services | NIH | Fogarty International Center","doi-asserted-by":"publisher","award":["D43TW006589"],"award-info":[{"award-number":["D43TW006589"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"U.S. Department of Health & Human Services | NIH | Fogarty International Center","doi-asserted-by":"publisher","award":["D43TW006589"],"award-info":[{"award-number":["D43TW006589"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["107595\/Z\/15\/Z"],"award-info":[{"award-number":["107595\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministerio de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n - Minciencias"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-58330-3","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:12:44Z","timestamp":1743811964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Innate biosignature of treatment failure in human cutaneous leishmaniasis"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8792-1563","authenticated-orcid":false,"given":"Mar\u00eda Adelaida","family":"G\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashton Trey","family":"Belew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6575-1919","authenticated-orcid":false,"given":"Deninson Alejandro","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-7249","authenticated-orcid":false,"given":"Lina","family":"Giraldo-Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9680-9108","authenticated-orcid":false,"given":"David E.","family":"Rebell\u00f3n-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa A.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7970-3312","authenticated-orcid":false,"given":"Najib M.","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"58330_CR1","unstructured":"WHO. Vector-borne diseases. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/vector-borne-diseases (2020)."},{"key":"58330_CR2","unstructured":"WHO\/TDR. Global Report for Research on Infectious Diseases of Poverty. (2012)."},{"key":"58330_CR3","unstructured":"WHO. Leishmaniasis: Status of endemicity of cutaneous leishmaniasis 2020. https:\/\/apps.who.int\/neglected_diseases\/ntddata\/leishmaniasis\/leishmaniasis.html (2020)."},{"key":"58330_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.actatropica.2011.02.007","volume":"118","author":"LF Oliveira","year":"2011","unstructured":"Oliveira, L. F. et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop. 118, 87\u201396 (2011).","journal-title":"Acta Trop."},{"key":"58330_CR5","unstructured":"PAHO. Guideline for the Treatment of Leishmaniasis in the Americas. (2022)."},{"key":"58330_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.4269\/ajtmh.18-0643","volume":"100","author":"AF Uribe-Restrepo","year":"2019","unstructured":"Uribe-Restrepo, A. F., Prieto, M. D., Cossio, A., Desai, M. M. & Del Mar Castro, M. Eligibility for local therapies in adolescents and adults with cutaneous leishmaniasis from southwestern Colombia: A cross-sectional study. Am. J. Trop. Med. Hyg. 100, 306\u2013310 (2019).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"58330_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0004273","volume":"9","author":"M Rosales-Chilama","year":"2015","unstructured":"Rosales-Chilama, M. et al. Parasitological confirmation and analysis of Leishmania diversity in asymptomatic and subclinical infection following resolution of cutaneous Leishmaniasis. PLoS Negl. Trop. Dis. 9, 1\u201320 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"58330_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1086\/505583","volume":"194","author":"C Vergel","year":"2006","unstructured":"Vergel, C. et al. Evidence for Leishmania (Viannia) parasites in the skin and blood of patients before and after treatment. J. Infect. Dis. 194, 503\u2013511 (2006).","journal-title":"J. Infect. Dis."},{"key":"58330_CR9","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.trstmh.2006.02.014","volume":"100","author":"P Camera","year":"2006","unstructured":"Camera, P. et al. Haematogenous dissemination of Leishmania (Viannia) braziliensis in human American tegumentary leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 100, 1112\u20131117 (2006).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"58330_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nri.2016.72","volume":"16","author":"P Scott","year":"2016","unstructured":"Scott, P. & Novais, F. O. Cutaneous leishmaniasis: Immune responses in protection and pathogenesis. Nat. Rev. Immunol. 16, 581\u2013592 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"58330_CR11","doi-asserted-by":"publisher","first-page":"E484","DOI":"10.1093\/cid\/ciaa1206","volume":"72","author":"MA G\u00f3mez","year":"2021","unstructured":"G\u00f3mez, M. A. et al. Immuno-pharmacokinetics of meglumine antimoniate in patients with cutaneous Leishmaniasis caused by Leishmania (Viannia). Clin. Infect. Dis. 72, E484\u2013E492 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"58330_CR12","first-page":"1","volume":"61","author":"M Del Mar Castro","year":"2017","unstructured":"Del Mar Castro, M. et al. Pharmacokinetics of miltefosine in children and adults with Cutaneous leishmaniasis. Antimicrob. Agents Chemother. 61, 1\u201311 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"58330_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/IAI.00764-19","volume":"88","author":"A Navas","year":"2020","unstructured":"Navas, A. et al. Profiles of local and systemic inflammation in the outcome of treatment of human cutaneous leishmaniasis caused by L. Viannia. Infect. Immun. 88, 1\u201312 (2020).","journal-title":"Infect. Immun."},{"key":"58330_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.04298-14","volume":"59","author":"AE Kip","year":"2015","unstructured":"Kip, A. E. et al. Systematic review of biomarkers to monitor therapeutic response in leishmaniasis. Antimicrob. Agents Chemother. 59, 1\u201314 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"58330_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aax4204","volume":"11","author":"CF Amorim","year":"2019","unstructured":"Amorim, C. F. et al. Variable gene expression and parasite load predict treatment outcome in cutaneous leishmaniasis. Sci. Transl. Med. 11, 1\u20139 (2019).","journal-title":"Sci. Transl. Med"},{"key":"58330_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/infdis\/jiv354","volume":"213","author":"V Adaui","year":"2016","unstructured":"Adaui, V. et al. Association of the endobiont double-stranded RNA virus LRV1 with treatment failure for human Leishmaniasis caused by Leishmania braziliensis in Peru and Bolivia. J. Infect. Dis. 213, 112\u2013121 (2016).","journal-title":"J. Infect. Dis."},{"key":"58330_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010162","volume":"16","author":"BM Valencia","year":"2022","unstructured":"Valencia, B. M. et al. Leishmania RNA virus-1 is similarly detected among metastatic and non-metastatic phenotypes in a prospective cohort of American Tegumentary Leishmaniasis. PLoS Negl. Trop. Dis. 16, e0010162 (2022).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"58330_CR18","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/infdis\/jiz538","volume":"221","author":"TM Campos","year":"2020","unstructured":"Campos, T. M. et al. Granzyme B produced by natural killer cells enhances inflammatory response and contributes to the immunopathology of cutaneous Leishmaniasis. J. Infect. Dis. 221, 973\u2013982 (2020).","journal-title":"J. Infect. Dis."},{"key":"58330_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/bioinformatics\/btaa687","volume":"37","author":"GE Hoffman","year":"2021","unstructured":"Hoffman, G. E. & Roussos, P. Dream: powerful differential expression analysis for repeated measures designs. Bioinformatics 37, 192\u2013201 (2021).","journal-title":"Bioinformatics"},{"key":"58330_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-016-1323-z","volume":"17","author":"GE Hoffman","year":"2016","unstructured":"Hoffman, G. E. & Schadt, E. E. variancePartition: interpreting drivers of variation in complex gene expression studies. BMC Bioinforma. 17, 483 (2016).","journal-title":"BMC Bioinforma."},{"key":"58330_CR21","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.3390\/cells10092406","volume":"10","author":"LW Garratt","year":"2021","unstructured":"Garratt, L. W. Current understanding of the neutrophil transcriptome in health and disease. Cells 10, 2406 (2021).","journal-title":"Cells"},{"key":"58330_CR22","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.celrep.2019.01.041","volume":"26","author":"G Monaco","year":"2019","unstructured":"Monaco, G. et al. RNA-Seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types. Cell Rep. 26, 1627\u20131640 (2019).","journal-title":"Cell Rep."},{"key":"58330_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nri3787","volume":"15","author":"F Mcnab","year":"2020","unstructured":"Mcnab, F., Mayer-barber, K., Sher, A., Wack, A. & Garra, A. O. Type I interferons in infectious disease. Nat. Rev. Immunol. 15, 87\u2013103 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"58330_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.tim.2018.08.007","volume":"27","author":"A Gregorio","year":"2019","unstructured":"Gregorio, A., Junior, D., Sampaio, N. G. & Rehwinkel, J. A balancing act: MDA5 in antiviral immunity and autoinflammation. Trends Microbiol. 27, 75\u201385 (2019).","journal-title":"Trends Microbiol."},{"key":"58330_CR25","doi-asserted-by":"publisher","first-page":"894","DOI":"10.4049\/jimmunol.2300576","volume":"212","author":"L Giraldo-Parra","year":"2024","unstructured":"Giraldo-Parra, L. et al. Consolidation of a molecular signature of healing in cutaneous Leishmaniasis Is achieved during the first 10 days of treatment. J. Immunol. 212, 894\u2013903 (2024).","journal-title":"J. Immunol."},{"key":"58330_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v028.i05","volume":"28","author":"M Kuhn","year":"2008","unstructured":"Kuhn, M. Building predictive models in R using the caret package. J. Stat. Softw. 28, 1\u201326 (2008).","journal-title":"J. Stat. Softw."},{"key":"58330_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.pt.2023.01.012","volume":"39","author":"MA Domagalska","year":"2023","unstructured":"Domagalska, M. A., Barrett, M. P. & Dujardin, J.-C. Drug resistance in Leishmania: does it really matter? Trends Parasitol. 39, 251\u2013259 (2023).","journal-title":"Trends Parasitol."},{"key":"58330_CR28","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1128\/IAI.68.1.288-293.2000","volume":"68","author":"HW Murray","year":"2000","unstructured":"Murray, H. W. & Delph-Etienne, S. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 68, 288\u2013293 (2000).","journal-title":"Infect. Immun."},{"key":"58330_CR29","doi-asserted-by":"publisher","first-page":"6289","DOI":"10.1128\/IAI.68.11.6289-6293.2000","volume":"68","author":"HW Murray","year":"2000","unstructured":"Murray, H. W., Jungbluth, A., Ritter, E., Montelibano, C. & Marino, M. W. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect. Immun. 68, 6289\u20136293 (2000).","journal-title":"Infect. Immun."},{"key":"58330_CR30","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1086\/315890","volume":"182","author":"HW Murray","year":"2000","unstructured":"Murray, H. W., Montelibano, C., Peterson, R. & Sypek, J. P. Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. J. Infect. Dis. 182, 1497\u20131502 (2000).","journal-title":"J. Infect. Dis."},{"key":"58330_CR31","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1084\/jem.189.4.741","volume":"189","author":"HW Murray","year":"1999","unstructured":"Murray, H. W. & Nathan, C. F. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 189, 741\u2013746 (1999).","journal-title":"J. Exp. Med."},{"key":"58330_CR32","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1172\/JCI114009","volume":"83","author":"HW Murray","year":"1989","unstructured":"Murray, H. W., Oca, M. J., Granger, A. M. & Schreiber, R. D. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J. Clin. Invest. 83, 1253\u20131257 (1989).","journal-title":"J. Clin. Invest."},{"key":"58330_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1179\/000349803225002606","volume":"97","author":"F Laguna","year":"2003","unstructured":"Laguna, F. Treatment of leishmaniasis in HIV-positive patients. Ann. Trop. Med. Parasitol. 97, 135\u2013142 (2003).","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"58330_CR34","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/jac\/dkg356","volume":"52","author":"F Laguna","year":"2003","unstructured":"Laguna, F. et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J. Antimicrob. Chemother. 52, 464\u2013468 (2003).","journal-title":"J. Antimicrob. Chemother."},{"key":"58330_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4269\/ajtmh.2001.64.187","volume":"64","author":"R Palacios","year":"2001","unstructured":"Palacios, R., Osorio, L. E., Grajales, L. F. & Ochoa, M. T. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am. J. Trop. Med. Hyg. 64, 187\u2013193 (2001).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"58330_CR36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4269\/ajtmh.2005.72.421","volume":"72","author":"J Soto","year":"2005","unstructured":"Soto, J., Toledo, J., Vega, J. & Berman, J. Short report: efficacy of pentavalent antimony for treatment of colombian cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 72, 421\u2013422 (2005).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"58330_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4269\/ajtmh.2010.10-0060","volume":"83","author":"I Velez","year":"2010","unstructured":"Velez, I. et al. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 83, 351\u2013356 (2010).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"58330_CR38","doi-asserted-by":"publisher","first-page":"7574","DOI":"10.4049\/jimmunol.172.12.7574","volume":"172","author":"J Mattner","year":"2004","unstructured":"Mattner, J. et al. Protection against progressive leishmaniasis by IFN-beta. J. Immunol. 172, 7574\u20137582 (2004).","journal-title":"J. Immunol."},{"key":"58330_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1074-7613(00)80460-4","volume":"8","author":"A Diefenbach","year":"1998","unstructured":"Diefenbach, A. et al. Type 1 interferon (IFNalpha\/beta) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite. Immunity 8, 77\u201387 (1998).","journal-title":"Immunity"},{"key":"58330_CR40","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1016\/j.celrep.2020.01.099","volume":"30","author":"R Kumar","year":"2020","unstructured":"Kumar, R. et al. Type I interferons suppress anti-parasitic immunity and can be targeted to improve treatment of visceral Leishmaniasis. Cell Rep. 30, 2512\u20132525.e9 (2020).","journal-title":"Cell Rep."},{"key":"58330_CR41","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","volume":"32","author":"WM Schneider","year":"2014","unstructured":"Schneider, W. M., Chevillotte, M. D. & Rice, C. M. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 32, 513\u2013545 (2014).","journal-title":"Annu. Rev. Immunol."},{"key":"58330_CR42","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","volume":"20","author":"FJ Barrat","year":"2019","unstructured":"Barrat, F. J., Crow, M. K. & Ivashkiv, L. B. Interferon target-gene expression and epigenomic signatures in health and disease. Nat. Immunol. 20, 1574\u20131583 (2019).","journal-title":"Nat. Immunol."},{"key":"58330_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature13489","volume":"511","author":"KD Mayer-Barber","year":"2014","unstructured":"Mayer-Barber, K. D. et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511, 99\u2013103 (2014).","journal-title":"Nature"},{"key":"58330_CR44","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09247","volume":"466","author":"MPR Berry","year":"2010","unstructured":"Berry, M. P. R. et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 973\u2013977 (2010).","journal-title":"Nature"},{"key":"58330_CR45","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1084\/jem.20050821","volume":"202","author":"GA Kolumam","year":"2005","unstructured":"Kolumam, G. A., Thomas, S., Thompson, L. J., Sprent, J. & Murali-Krishna, K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202, 637\u2013650 (2005).","journal-title":"J. Exp. Med."},{"key":"58330_CR46","doi-asserted-by":"publisher","first-page":"555","DOI":"10.4269\/ajtmh.22-0551","volume":"108","author":"M Rosales-Chilama","year":"2023","unstructured":"Rosales-Chilama, M., Oviedo, M. Y., Quintero, Y. K., Fernandez, O. L. & Gomez, M. A. Leishmania RNA Virus Is Not Detected in All Species of the Leishmania Viannia Subgenus: The Case of L. (V.) panamensis in Colombia. Am. J. Trop. Med. Hyg. 108, 555\u2013560 (2023).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"58330_CR47","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1128\/IAI.01388-10","volume":"79","author":"C Gallego","year":"2011","unstructured":"Gallego, C., Golenbock, D., Gomez, M. A. & Saravia, N. G. Toll-like receptors participate in macrophage activation and intracellular control of Leishmania (Viannia) panamensis. Infect. Immun. 79, 2871\u20132879 (2011).","journal-title":"Infect. Immun."},{"key":"58330_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.687607","volume":"11","author":"MA Gomez","year":"2021","unstructured":"Gomez, M. A. et al. Early leukocyte responses in ex-vivo models of healing and non-healing human Leishmania (Viannia) panamensis infections. Front. Cell Infect. Microbiol. 11, 687607 (2021).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"58330_CR49","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/pathogens11030378","volume":"11","author":"MDM Castro","year":"2022","unstructured":"Castro, M. D. M. et al. Pentoxifylline in the treatment of cutaneous Leishmaniasis: A randomized clinical trial in Colombia. Pathogens 11, 378 (2022).","journal-title":"Pathogens"},{"key":"58330_CR50","first-page":"CD004834","volume":"8","author":"M Pinart","year":"2020","unstructured":"Pinart, M. et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst. Rev. 8, CD004834 (2020).","journal-title":"Cochrane Database Syst. Rev."},{"key":"58330_CR51","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1001\/archderm.142.12.1575","volume":"142","author":"A Firooz","year":"2006","unstructured":"Firooz, A. et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch. Dermatol. 142, 1575\u20131579 (2006).","journal-title":"Arch. Dermatol."},{"key":"58330_CR52","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1093\/infdis\/172.6.1627","volume":"172","author":"S Sundar","year":"1995","unstructured":"Sundar, S. & Murray, H. W. Effect of treatment with interferon-\u03b3 alone in visceral Leishmaniasis. J. Infect. Dis. 172, 1627\u20131629 (1995).","journal-title":"J. Infect. Dis."},{"key":"58330_CR53","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/diagnostics9030113","volume":"9","author":"A Pin","year":"2019","unstructured":"Pin, A. et al. An easy and reliable strategy for making type I interferon signature analysis comparable among research centers. Diagnostics 9, 113 (2019).","journal-title":"Diagnostics"},{"key":"58330_CR54","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1073\/pnas.0337679100","volume":"100","author":"EC Baechler","year":"2003","unstructured":"Baechler, E. C. et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100, 2610\u20132615 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"58330_CR55","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1089\/jir.2017.0127","volume":"38","author":"H Kim","year":"2018","unstructured":"Kim, H. et al. Development of a validated interferon score using NanoString Technology. J. Interf. Cytokine Res. 38, 171\u2013185 (2018).","journal-title":"J. Interf. Cytokine Res."},{"key":"58330_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-015-0108-y","volume":"8","author":"A Alyass","year":"2015","unstructured":"Alyass, A., Turcotte, M. & Meyre, D. From big data analysis to personalized medicine for all: challenges and opportunities. BMC Med. Genomics 8, 33 (2015).","journal-title":"BMC Med. Genomics"},{"key":"58330_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12688\/wellcomeopenres.18052.2","volume":"7","author":"L Giraldo-Parra","year":"2023","unstructured":"Giraldo-Parra, L., Ramirez, L. G., Navas, A. & G\u00f3mez, M. A. Quality parameters for RNA preparations from biopsies of ulcerated human skin. Wellcome Open Res. 7, 1\u201313 (2023).","journal-title":"Wellcome Open Res."},{"key":"58330_CR58","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1590\/S0074-02761996000100006","volume":"91","author":"G Grimaldi","year":"1996","unstructured":"Grimaldi, G. & McMahon-Pratt, D. Monoclonal antibodies for the identification of New World Leishmania species. Mem. Inst. Oswaldo Cruz 91, 37\u201342 (1996).","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"58330_CR59","doi-asserted-by":"publisher","first-page":"e2871","DOI":"10.1371\/journal.pntd.0002871","volume":"8","author":"OL Fernandez","year":"2014","unstructured":"Fernandez, O. L. et al. Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia. PLoS Negl. Trop. Dis. 8, e2871 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"58330_CR60","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1128\/JCM.00216-12","volume":"50","author":"O Fern\u00e1ndez","year":"2012","unstructured":"Fern\u00e1ndez, O. et al. Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp. J. Clin. Microbiol. 50, 2207\u20132211 (2012).","journal-title":"J. Clin. Microbiol."},{"key":"58330_CR61","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114\u20132120 (2014).","journal-title":"Bioinformatics"},{"key":"58330_CR62","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","volume":"37","author":"D Kim","year":"2019","unstructured":"Kim, D., Paggi, J. M., Park, C., Bennett, C. & Salzberg, S. L. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat. Biotechnol. 37, 907\u2013915 (2019).","journal-title":"Nat. Biotechnol."},{"key":"58330_CR63","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H., Handsaker, B., Wysoker, A. & Fennell, T. The sequence alignment\/Map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"58330_CR64","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Theodor Pyl, P. & Huber, W. HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"58330_CR65","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The SVA package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882\u2013883 (2012).","journal-title":"Bioinformatics"},{"key":"58330_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, 1\u201313 (2015).","journal-title":"Nucleic Acids Res."},{"key":"58330_CR67","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"58330_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 1\u201321 (2014).","journal-title":"Genome Biol."},{"key":"58330_CR69","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1093\/bioinformatics\/btt087","volume":"29","author":"N Leng","year":"2013","unstructured":"Leng, N. et al. EBSeq: An empirical Bayes hierarchical model for inference in RNA-seq experiments. Bioinformatics 29, 1035\u20131043 (2013).","journal-title":"Bioinformatics"},{"key":"58330_CR70","doi-asserted-by":"publisher","first-page":"18","DOI":"10.14806\/ej.17.B.265","volume":"17","author":"S Tarazona","year":"2012","unstructured":"Tarazona, S., Garc\u00eda, F., Ferrer, A., Dopazo, J. & Conesa, A. NOIseq: a RNA-seq differential expression method robust for sequencing depth biases. EMBnet. J. 17, 18 (2012).","journal-title":"EMBnet. J."},{"key":"58330_CR71","doi-asserted-by":"publisher","first-page":"W207","DOI":"10.1093\/nar\/gkad347","volume":"51","author":"L Kolberg","year":"2023","unstructured":"Kolberg, L. et al. G:Profiler-interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update). Nucleic Acids Res. 51, W207\u2013W212 (2023).","journal-title":"Nucleic Acids Res."},{"key":"58330_CR72","first-page":"284","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R Package for comparing biological themes among gene clusters. J. Integr. Biol. 16, 284\u2013287 (2012).","journal-title":"J. Integr. Biol."},{"key":"58330_CR73","doi-asserted-by":"publisher","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","volume":"49","author":"D Szklarczyk","year":"2021","unstructured":"Szklarczyk, D. et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets. Nucleic Acids Res. 49, D605\u2013D612 (2021).","journal-title":"Nucleic Acids Res."},{"key":"58330_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 14, 7 (2013).","journal-title":"BMC Bioinforma."},{"key":"58330_CR75","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"58330_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1891-0","volume":"20","author":"DE Wood","year":"2019","unstructured":"Wood, D. E., Lu, J. & Langmead, B. Improved metagenomic analysis with Kraken 2. Genome Biol. 20, 257 (2019).","journal-title":"Genome Biol."},{"key":"58330_CR77","first-page":"427","volume":"78","author":"CR Mehta","year":"1983","unstructured":"Mehta, C. R. & Patel, N. R. A network algorithm for performing fisher\u2019s exact test in r \u00d7 c contingency tables. J. Am. Stat. Assoc. 78, 427\u2013434 (1983).","journal-title":"J. Am. Stat. Assoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58330-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58330-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58330-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T13:03:32Z","timestamp":1743944612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58330-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["58330"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-58330-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4271873\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"15 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3235"}}